Arkolith/Funds/TRV GP V, LLC

TRV GP V, LLC

CIK 1990717
Holdings as of Jun 30, 2026·disclosed Aug 10, 2026·~41-day 13F lag·13F-HR
Active Filer

TRV GP V, LLC holds a concentrated book of 3 stocks worth $498.2M as of Q2 2026 (disclosed Aug 10, 2026, a ~41-day 13F lag). This quarter they opened Cargo Therapeutics Inc and trimmed Rapport Therapeutics Inc. Their largest long position is Rapport Therapeutics Inc at 53% of the equity book.

Opened
1
bought for the first time
Added to
0
already held, bought more
no adds
Trimmed
1
sold some, still holds it
Sold out
0
exited the position entirely
nothing exited

Concentration

Top-heavy: concentrated book

Top 5 holdings
100%
Top 10 holdings
100%
Top 20 holdings
100%

Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.

Direct sector allocation

100% mapped to company sectors

Health Care
100%

Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.

Biggest moves: latest quarter

Estimated $ traded · quarter-end prices, no cost basis

Bought

No buys this quarter.

Trimmed / exited

Funds with the most overlap

Other tracked managers holding the same core names as TRV GP V, LLC

Manager / fundShared namesTheir $ in those
FMR LLC3 / 3$250.7M
BlackRock, Inc.3 / 3$198.9M
GOLDMAN SACHS GROUP INC3 / 3$170.3M
VANGUARD CAPITAL MANAGEMENT LLC3 / 3$113.1M
JANUS HENDERSON GROUP PLC3 / 3$107.0M
STATE STREET CORP3 / 3$85.7M
GEODE CAPITAL MANAGEMENT, LLC3 / 3$81.4M
ADAGE CAPITAL PARTNERS GP, L.L.C.3 / 3$40.4M

Ranked by how many of TRV GP V, LLC's top 3 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.

Holdings: largest first

Bars show each stock's share of the portfolio. Click a row for its position history.

3 positions
#SecurityValueShares% PortLast moveHistory
1Rapport Therapeutics, Inc.
COM
$261.7M6.28M
52.5%
−12%
Reduced · −855K sh
2Septerna, Inc.
COM
$208.2M6.22M
41.8%
Held
3Maze Therapeutics, Inc.
COM
$28.4M950.8K
5.7%
Held
Showing all 3 positions
Build

Build on this 13F portfolio

The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.

Build

Ask your agent what TRV GP V, LLC owns

This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.

Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/funds/1990717/holdings"
Ask your agent
Use Arkolith to show TRV GP V, LLC's latest
holdings, largest changes, and filing provenance.

Filing history

As-of date vs the date the SEC received each filing

QuarterAs ofFiledPositionsValueForm
Q2 2026Jun 30, 2026Aug 10, 20263$498.2M13F-HR
Q1 2026Mar 31, 2026May 7, 20263$401.0M13F-HR
Q4 2025Dec 31, 2025Feb 13, 20263$429.2M13F-HR
Q3 2025Sep 30, 2025Nov 13, 20253$353.5M13F-HR
Q2 2025Jun 30, 2025Aug 8, 20254$165.7M13F-HR
Q1 2025Mar 31, 2025May 9, 20254$125.1M13F-HR
Q4 2024Dec 31, 2024Feb 13, 20253$294.0M13F-HR

Data source

Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.